Saxagliptin (Onglyza®)
All Wales Medicines Strategy Group (AWMSG)
Record ID 32012000351
English
Authors' recommendations:
Saxagliptin (Onglyza®) is recommended as an option for use within NHS Wales as an add-on combination therapy for use in adult patients with type 2 diabetes mellitus with moderate or severe renal impairment to improve glycaemic control.
AWMSG is of the opinion that saxagliptin (Onglyza®) may be suitable for shared care within NHS Wales.
Details
Project Status:
Completed
Year Published:
2011
URL for published report:
http://www.wales.nhs.uk/sites3/docmetadata.cfm?orgid=371&id=184838&pid=24773
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Wales, United Kingdom
MeSH Terms
- Dipeptidyl-Peptidase IV Inhibitors
- Incretins
- Diabetes Mellitus, Type 2
- Hypoglycemic Agents
Contact
Organisation Name:
All Wales Medicines Strategy Group
Contact Address:
All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX
Contact Name:
AWTTC@wales.nhs.uk
Contact Email:
AWTTC@wales.nhs.uk
Copyright:
AWTTC
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.